⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

VK2809 (VK2809) | Accelerate Your Fibrosis Research

Home/Drugs/VK2809

VK2809

VK2809

Phase 2b

Sponsor: Viking Therapeutics

Indication: MASH

Mechanism of Action

THR-β Agonist

Target: THR-beta

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT02927184

Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

Phase:PHASE2Org:Viking Therapeutics, Inc.

COMPLETED

Relevant Publications (PubMed)

No recent publications found for VK2809.

Validated Models

This drug has been validated in the following preclinical models:

NCT04173065

A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH

Phase:PHASE2Org:Viking Therapeutics, Inc.

View all trials on ClinicalTrials.gov